Pluristem Therapeutics Inc., of Haifa, Israel, said its licensee, United Therapeutics Corp., of Silver Spring, Md., has completed the dosing of the first cohort of patients in its phase I study using Pluristem's placental expanded cells in patients diagnosed with pulmonary arterial hypertension.